LncRNA-MIAT Increased in Patients with Coronary Atherosclerotic Heart Disease
Background. To study the expression and clinical significance of long noncoding RNA- (lncRNA-) MIAT in patients with coronary atherosclerotic heart disease (CAD). Methods. Serum MIAT, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) in 106 CAD patients and 89 healthy donors were detected. C...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2019-01-01
|
| Series: | Cardiology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2019/6280194 |
| Summary: | Background. To study the expression and clinical significance of long noncoding RNA- (lncRNA-) MIAT in patients with coronary atherosclerotic heart disease (CAD). Methods. Serum MIAT, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) in 106 CAD patients and 89 healthy donors were detected. Correlations between serum MIAT and serum IL-6 and TNF-α were analyzed. Risk factors for patients with CAD were analyzed by multiple factor analysis. Results. Compared with healthy donors, serum lncRNA-MIAT was significantly increased in CAD patients. Serum MIAT was positively correlated with serum IL-6 and TNF-α in CAD. Multivariate analysis found that hypertension (OR (95% CI) = 3.471 (2.180–4.091), P=0.011), diabetes (OR (95% CI) = 3.682 (1.698–4.897), P=0.003), HDL-C (OR (95% CI) = 3.372 (1.760–6.920), P=0.001), and serum MIAT expression (OR (95% CI) = 2.687 (1.683–7.468), P=0.001) were independent risk factors for CAD. Conclusions. Serum lncRNA-MIAT in CAD patients was significantly increased, which may be a potential marker for diagnosis and prognosis of CAD. |
|---|---|
| ISSN: | 2090-8016 2090-0597 |